Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

277
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
277
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
174
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

207
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
207

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fused 1H-/2H-Indazole as Bioactive Privileged Scaffolds: Synthetic Strategies and Pharmaceutical Applications.

Current drug discovery technologies·2026
Same author

Correction to "An Unusual Ring Pattern in the Rosβ Lanthipeptide of the Two-Component Lantibiotic Roseocin".

Journal of natural products·2026
Same author

Solar-Driven Artificial Photosynthesis: Solar-Active D-Ï€-A-COFs Photocatalyst Using Cobalt Complex for CO<sub>2</sub> Fixation and Difluoroalkylation via HAT Pathways.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

Green and sustainable approaches towards synthesis of anticancer bioheterocycles via microwave irradiation.

Bioorganic chemistry·2026
Same author

The gut microbiome axis: how Lactobacillus-fermented soymilk orchestrates health.

Archives of microbiology·2026
Same author

Earth-Abundant Transition Metals Catalyzed Alkylation, Alkenylation, and Alkynylation of Arenes via Cross Dehydrogenative Coupling (CDC): Synthetic Strategies and Mechanistic Pathways.

Topics in current chemistry (Cham)·2026
Same journal

Continuous Glucose Monitoring in Type 2 Diabetes: Clinical Outcomes, Disparities in Access, and Cost-effectiveness.

Current diabetes reports·2026
Same journal

Beyond Inflammation - A Multidisciplinary Approach to Managing Obesity and Cardiometabolic Risk in Inflammatory Bowel Disease.

Current diabetes reports·2026
Same journal

Climate Change and Diabetes Outcomes: Evidence from Climate-Vulnerable Regions.

Current diabetes reports·2026
Same journal

Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis.

Current diabetes reports·2026
Same journal

Use of Glucagon-Like Peptide-1 Receptor Agonists in Women with Type 2 Diabetes Before Pregnancy: Addressing the Dilemma in A Real-World Setting.

Current diabetes reports·2026
Same journal

Can Behavioral Interventions Promote Health Equity in Pediatric Type 1 Diabetes? A Narrative Review of Promising Treatments.

Current diabetes reports·2026
See all related articles

Related Experiment Video

Updated: Jun 29, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.6K

Metformin: Past, Present, and Future.

Sandeep Chaudhary1, Amitabh Kulkarni2

  • 1NMC Specialty Hospital, Al Nahda 1, Dubai, United Arab Emirates. sandeepch8j@gmail.com.

Current Diabetes Reports
|April 3, 2024
PubMed
Summary
This summary is machine-generated.

Metformin remains a leading oral antihyperglycemic for type 2 diabetes. Research is exploring its potential benefits in various other conditions beyond diabetes management.

Keywords:
Gestational diabetesMetforminPolycystic ovary syndrome (PCOS)Type 2 diabetes mellitus

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.2K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K

Related Experiment Videos

Last Updated: Jun 29, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.6K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.2K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Metformin is a widely used biguanide oral antihyperglycemic agent.
  • It is the preferred first-line treatment for type 2 diabetes mellitus globally.
  • Its efficacy, availability, and established safety profile contribute to its continued dominance.

Purpose of the Study:

  • To provide an updated review of metformin's role in managing type 2 diabetes mellitus.
  • To explore emerging research on metformin's potential applications in other diseases.
  • To summarize recent findings and clinical considerations for metformin use.

Main Methods:

  • Review of current literature and recent studies on metformin.
  • Analysis of metformin's pharmacological mechanisms of action.
  • Synthesis of clinical data regarding efficacy, safety, and novel applications.

Main Results:

  • Metformin effectively lowers glucose by reducing hepatic production, decreasing intestinal absorption, and enhancing insulin sensitivity.
  • It can be used as monotherapy or in combination with other antidiabetics.
  • Emerging research suggests potential benefits in polycystic ovarian disease, gestational diabetes, cognitive disorders, and immunological diseases.

Conclusions:

  • Metformin remains a cornerstone therapy for type 2 diabetes mellitus.
  • Further extensive studies are required to validate metformin's additional therapeutic benefits in non-diabetic conditions.
  • Careful consideration of renal function and potential side effects like Vitamin B12 deficiency is necessary.